

Catherijne A J Knibbe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2343530/publications.pdf>

Version: 2024-02-01

152
papers

5,206
citations

70961

41
h-index

106150

65
g-index

156
all docs

156
docs citations

156
times ranked

4988
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of Obesity on Drug Metabolism and Elimination in Adults and Children. <i>Clinical Pharmacokinetics</i> , 2012, 51, 277-304.	1.6	288
2	Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , 2015, 2, e194-e203.	2.2	228
3	The role of population PK/PD modelling in paediatric clinical research. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 5-16.	0.8	175
4	Why Has Model-Informed Precision Dosing Not Yet Become Common Clinical Reality? Lessons From the Past and a Roadmap for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 646-656.	2.3	169
5	Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a retrospective, pharmacodynamic cohort analysis. <i>Lancet Haematology</i> , 2017, 4, e183-e191.	2.2	154
6	Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 275-285.	1.5	135
7	Morphine Glucuronidation in Preterm Neonates, Infants and Children Younger than 3 Years. <i>Clinical Pharmacokinetics</i> , 2009, 48, 371-385.	1.6	129
8	Body Weight-Dependent Pharmacokinetics of Busulfan in Paediatric Haematopoietic Stem Cell Transplantation Patients. <i>Clinical Pharmacokinetics</i> , 2012, 51, 331-345.	1.6	115
9	Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 715-723.	1.3	113
10	Maturation of the Glomerular Filtration Rate in Neonates, as Reflected by Amikacin Clearance. <i>Clinical Pharmacokinetics</i> , 2012, 51, 105-117.	1.6	99
11	Drug Disposition in Obesity: Toward Evidence-Based Dosing. <i>Annual Review of Pharmacology and Toxicology</i> , 2015, 55, 149-167.	4.2	99
12	Integrating clinical metabolomics-based biomarker discovery and clinical pharmacology to enable precision medicine. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S15-S21.	1.9	92
13	Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?. <i>Clinical Pharmacokinetics</i> , 2017, 56, 273-285.	1.6	86
14	Inflammation and Organ Failure Severely Affect Midazolam Clearance in Critically Ill Children. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 58-66.	2.5	81
15	Pharmacokinetics and Pharmacodynamics of Posaconazole. <i>Drugs</i> , 2020, 80, 671-695.	4.9	80
16	Population Pharmacokinetic Modeling of Thymoglobulin® in Children Receiving Allogeneic-Hematopoietic Cell Transplantation: Towards Improved Survival Through Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2015, 54, 435-446.	1.6	79
17	Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. <i>Clinical Pharmacokinetics</i> , 2016, 55, 833-847.	1.6	76
18	Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers. <i>Clinical Pharmacokinetics</i> , 2014, 53, 931-941.	1.6	72

#	ARTICLE	IF	CITATIONS
19	Evidence-Based Morphine Dosing for Postoperative Neonates and Infants. <i>Clinical Pharmacokinetics</i> , 2014, 53, 553-563.	1.6	70
20	Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-physiological Function for Maturation in Glomerular Filtration. <i>Pharmaceutical Research</i> , 2014, 31, 2643-2654.	1.7	70
21	A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span. <i>Pharmaceutical Research</i> , 2012, 29, 1570-1581.	1.7	67
22	A Neonatal Amikacin Covariate Model Can Be Used to Predict Ontogeny of Other Drugs Eliminated Through Glomerular Filtration in Neonates. <i>Pharmaceutical Research</i> , 2014, 31, 754-767.	1.7	67
23	Population Pharmacokinetics and Pharmacodynamics of Propofol in Morbidly Obese Patients. <i>Clinical Pharmacokinetics</i> , 2011, 50, 739-750.	1.6	65
24	A randomized controlled trial of daily sedation interruption in critically ill children. <i>Intensive Care Medicine</i> , 2016, 42, 233-244.	3.9	64
25	Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. <i>Metabolomics</i> , 2017, 13, 9.	1.4	64
26	Prediction of Propofol Clearance in Children from an Allometric Model Developed in Rats, Children and Adults versus a 0.75 Fixed-Exponent Allometric Model. <i>Clinical Pharmacokinetics</i> , 2010, 49, 269-275.	1.6	61
27	The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. <i>Pharmaceutical Research</i> , 2015, 32, 3927-3936.	1.7	58
28	Tailor-made drug treatment for children. <i>Drug Discovery Today</i> , 2009, 14, 316-320.	3.2	56
29	Systematic Evaluation of the Descriptive and Predictive Performance of Paediatric Morphine Population Models. <i>Pharmaceutical Research</i> , 2011, 28, 797-811.	1.7	56
30	Towards Rational Dosing Algorithms for Vancomycin in Neonates and Infants Based on Population Pharmacokinetic Modeling. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1013-1021.	1.4	53
31	Developmental Changes in Morphine Clearance Across the Entire Paediatric Age Range are Best Described by a Bodyweight-Dependent Exponent Model. <i>Clinical Drug Investigation</i> , 2013, 33, 523-534.	1.1	52
32	Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2016, 55, 507-524.	1.6	52
33	Predictive Performance of a Recently Developed Population Pharmacokinetic Model for Morphine and its Metabolites in New Datasets of (Preterm) Neonates, Infants and Children. <i>Clinical Pharmacokinetics</i> , 2011, 50, 51-63.	1.6	51
34	The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 149-159.	1.1	50
35	Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 659-669.	1.6	50
36	Propofol Pharmacokinetics and Pharmacodynamics for Depth of Sedation in Nonventilated Infants after Major Craniofacial Surgery. <i>Anesthesiology</i> , 2006, 104, 466-474.	1.3	47

#	ARTICLE	IF	CITATIONS
37	Novel model-based dosing guidelines for gentamicin and tobramycin in preterm and term neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2074-2077.	1.3	47
38	Individualized dosing regimens in children based on population PKPD modelling: Are we ready for it?. <i>International Journal of Pharmaceutics</i> , 2011, 415, 9-14.	2.6	46
39	Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. <i>Archives of Disease in Childhood</i> , 2014, 99, 267-272.	1.0	46
40	Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. <i>Drugs</i> , 2018, 78, 1887-1901.	4.9	44
41	Population pharmacokinetics of paracetamol across the human age range from (pre)term neonates, infants, children to adults. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 619-629.	1.0	42
42	Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial. <i>Nutrition and Diabetes</i> , 2016, 6, e228-e228.	1.5	42
43	A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults. <i>Clinical Pharmacokinetics</i> , 2013, 52, 555-565.	1.6	41
44	Prospective Evaluation of a Model-Based Dosing Regimen for Amikacin in Preterm and Term Neonates in Clinical Practice. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6344-6351.	1.4	41
45	Advances in paediatric pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1-8.	1.5	39
46	Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1185-1196.	1.1	38
47	Influence of Morbid Obesity on the Pharmacokinetics of Morphine, Morphine-3-Glucuronide, and Morphine-6-Glucuronide. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1577-1587.	1.6	38
48	Evidence-based drug treatment for special patient populations through model-based approaches. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S22-S26.	1.9	37
49	Non-maturational covariates for dynamic systems pharmacology models in neonates, infants, and children: Filling the gaps beyond developmental pharmacology. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S27-S31.	1.9	37
50	Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 303-317.	1.1	37
51	Randomized clinical trial of extended <i>versus</i> single-dose perioperative antibiotic prophylaxis for acute calculous cholecystitis. <i>British Journal of Surgery</i> , 2017, 104, e151-e157.	0.1	36
52	Randomized Controlled Trial on the Influence of Intraoperative Remifentanil versus Fentanyl on Acute and Chronic Pain after Cardiac Surgery. <i>Pain Practice</i> , 2018, 18, 443-451.	0.9	35
53	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part I – Extrapolation of a Covariate Model From Morphine to Zidovudine. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012, 1, 1-9.	1.3	34
54	Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1330-1338.	1.3	31

#	ARTICLE	IF	CITATIONS
55	From Pediatric Covariate Model to Semiphysiological Function for Maturation: Part II – Sensitivity to Physiological and Physicochemical Properties. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2012, 1, 1-8.	1.3	30
56	Developmental changes rather than repeated administration drive paracetamol glucuronidation in neonates and infants. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1075-1082.	0.8	30
57	Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite – midazolam in morbidly obese and weight loss surgery patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 20-30.	1.3	30
58	Pediatric Microdose Study of [¹⁴ C]Paracetamol to Study Drug Metabolism Using Accelerated Mass Spectrometry: Proof of Concept. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1045-1051.	1.6	29
59	Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. <i>Archives of Disease in Childhood</i> , 2015, 100, 763-768.	1.0	29
60	Commentary on the EMA Reflection Paper on the use of extrapolation in the development of medicines for paediatrics. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 659-668.	1.1	28
61	Population Pharmacokinetics of Alemtuzumab (Campath) in Pediatric Hematopoietic Cell Transplantation: Towards Individualized Dosing to Improve Outcome. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1609-1620.	1.6	27
62	Amikacin Pharmacokinetics To Optimize Dosing in Neonates with Perinatal Asphyxia Treated with Hypothermia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	26
63	Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 109, S90-S97.	1.9	26
64	Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 358-368.	1.1	25
65	Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults. <i>Clinical Pharmacokinetics</i> , 2018, 57, 601-611.	1.6	25
66	Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 786-795.	2.3	25
67	Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach. <i>Pharmaceutical Research</i> , 2018, 35, 182.	1.7	24
68	Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1235-1244.	1.3	23
69	Paracetamol and morphine for infant and neonatal pain; still a long way to go?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 111-126.	1.3	23
70	First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 374-383.	1.3	23
71	Oral drug dosing following bariatric surgery: General concepts and specific dosing advice. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4560-4576.	1.1	23
72	Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial. <i>Paediatric Drugs</i> , 2018, 20, 365-374.	1.3	22

#	ARTICLE	IF	CITATIONS
73	Rapidly maturing fentanyl clearance in preterm neonates. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2019, 104, F598-F603.	1.4	22
74	Successful Use of [¹⁴ C]Paracetamol Microdosing to Elucidate Developmental Changes in Drug Metabolism. Clinical Pharmacokinetics, 2017, 56, 1185-1195.	1.6	19
75	Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 175-185.	1.3	19
76	Long-term metformin treatment in adolescents with obesity and insulin resistance, results of an open label extension study. Nutrition and Diabetes, 2018, 8, 47.	1.5	18
77	The Influence of Drug Properties and Ontogeny of Transporters on Pediatric Renal Clearance through Glomerular Filtration and Active Secretion: a Simulation-Based Study. AAPS Journal, 2020, 22, 87.	2.2	18
78	Implications for IV posaconazole dosing in the era of obesity. Journal of Antimicrobial Chemotherapy, 2020, 75, 1006-1013.	1.3	18
79	Prediction of Morphine Clearance in the Paediatric Population. Clinical Pharmacokinetics, 2012, 51, 695-709.	1.6	17
80	Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. European Journal of Clinical Pharmacology, 2015, 71, 25-34.	0.8	17
81	Towards personalized treatment of pain using a quantitative systems pharmacology approach. European Journal of Pharmaceutical Sciences, 2017, 109, S32-S38.	1.9	17
82	Enantiomer specific pharmacokinetics of ibuprofen in preterm neonates with patent ductus arteriosus. British Journal of Clinical Pharmacology, 2020, 86, 2028-2039.	1.1	17
83	Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Research Protocols, 2017, 6, e136.	0.5	17
84	An Integrated Population Pharmacokinetic Meta-Analysis of Propofol in Morbidly Obese and Nonobese Adults, Adolescents, and Children. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8.	1.3	16
85	Paracetamol pharmacokinetics and metabolism in young women. BMC Anesthesiology, 2015, 15, 163.	0.7	16
86	Children Are Not Small Adults, but Can We Treat Them As Such?. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 34-38.	1.3	16
87	Dose-linearity of the pharmacokinetics of an intravenous [¹⁴ C]midazolam microdose in children. British Journal of Clinical Pharmacology, 2019, 85, 2332-2340.	1.1	15
88	Anti-Xa Levels 4h After Subcutaneous Administration of 5,700 IU Nadroparin Strongly Correlate with Lean Body Weight in Morbidly Obese Patients. Obesity Surgery, 2012, 22, 791-796.	1.1	14
89	METFORMIN: an efficacy, safety and pharmacokinetic study on the short-term and long-term use in obese children and adolescents - study protocol of a randomized controlled study. Trials, 2014, 15, 207.	0.7	14
90	Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 417-428.	1.5	14

#	ARTICLE	IF	CITATIONS
91	Simulation-based suggestions to improve ibuprofen dosing for patent ductus arteriosus in preterm newborns. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1585-1591.	0.8	14
92	Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 112.	1.7	13
93	Vancomycin pharmacokinetic models: informing the clinical management of drug-resistant bacterial infections. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 1371-1388.	2.0	12
94	Infants Operated on for Necrotizing Enterocolitis: Towards Evidence-Based Pain Guidelines. <i>Neonatology</i> , 2016, 110, 190-197.	0.9	12
95	Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1â€“18 Years. <i>AAPS Journal</i> , 2021, 23, 53.	2.2	12
96	Population-Based Cohort Study of Anti-Infective Medication Use before and after the Onset of Type 1 Diabetes in Children and Adolescents. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4666-4674.	1.4	11
97	Morphine Pharmacodynamics in Mechanically Ventilated Preterm Neonates Undergoing Endotracheal Suctioning. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 239-248.	1.3	11
98	Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1300-1308.	1.0	11
99	A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1333-1343.	1.6	11
100	Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method. <i>AAPS Journal</i> , 2019, 21, 38.	2.2	11
101	Enteral Acetaminophen Bioavailability in Pediatric Intensive Care Patients Determined With an Oral Microtracer and Pharmacokinetic Modeling to Optimize Dosing. <i>Critical Care Medicine</i> , 2019, 47, e975-e983.	0.4	11
102	Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 847-855.	1.0	10
103	The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1291-1301.	1.6	10
104	Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium. <i>Clinical and Translational Science</i> , 2021, 14, 29-35.	1.5	10
105	An Update on the Use of Allometric and Other Scaling Methods to Scale Drug Clearance in Children: Towards Decision Tables. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 99-113.	1.5	10
106	Perioperative antibiotic prophylaxis in the treatment of acute cholecystitis (PEANUTS II trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 390.	0.7	9
107	Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	9
108	Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3286-3292.	1.3	9

#	ARTICLE	IF	CITATIONS
109	Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1361-1372.	1.6	9
110	Antibiotic prophylaxis for acute cholecystectomy: PEANUTS II multicentre randomized non-inferiority clinical trial. <i>British Journal of Surgery</i> , 2022, 109, 267-273.	0.1	9
111	Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals: A Prospective Clinical Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1167-1175.	1.6	9
112	Is indirect hyperbilirubinemia a useful biomarker of reduced propofol clearance in neonates?. <i>Biomarkers in Medicine</i> , 2012, 6, 283-289.	0.6	8
113	Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 294-303.	1.1	8
114	Dose evaluation of lamivudine in human immunodeficiency virusâ€infecteâ€d children aged 5â€months to 18â€years based on a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1287-1297.	1.1	8
115	Body weight, gender and pregnancy affect enantiomerâ€specific ketorolac pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1966-1975.	1.1	8
116	Kernel-Based Visual Hazard Comparison (kbVHC): a Simulation-Free Diagnostic for Parametric Repeated Time-to-Event Models. <i>AAPS Journal</i> , 2018, 20, 5.	2.2	8
117	Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory. <i>Pharmaceutical Research</i> , 2018, 35, 209.	1.7	8
118	A Pediatric Covariate Function for CYP3A-Mediated Midazolam Clearance Can Scale Clearance of Selected CYP3A Substrates in Children. <i>AAPS Journal</i> , 2019, 21, 81.	2.2	8
119	The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models. <i>Clinical Pharmacokinetics</i> , 2019, 58, 131-138.	1.6	8
120	What is the dose of intravenous paracetamol for pain relief in neonates?. <i>Archives of Disease in Childhood</i> , 2017, 102, 649-650.	1.0	7
121	Rapid Increase in Clearance of Phenobarbital in Neonates on Extracorporeal Membrane Oxygenation: A Pilot Retrospective Population Pharmacokinetic Analysis. <i>Pediatric Critical Care Medicine</i> , 2020, 21, e707-e715.	0.2	7
122	The bioavailability and maturing clearance of doxapram in preterm infants. <i>Pediatric Research</i> , 2021, 89, 1268-1277.	1.1	7
123	The association of polypharmacy with functional decline in elderly patients undergoing cardiac surgery. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	7
124	Pediatric pharmacology: current efforts and future goals to improve clinical practice. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1679-1682.	1.5	6
125	Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. <i>BMC Anesthesiology</i> , 2019, 19, 15.	0.7	6
126	Estimation of Ontogeny Functions for Renal Transporters Using a Combined Population Pharmacokinetic and Physiology-Based Pharmacokinetic Approach: Application to OAT1,3. <i>AAPS Journal</i> , 2021, 23, 65.	2.2	6

#	ARTICLE	IF	CITATIONS
127	Prediction of glomerular filtration rate maturation across preterm and term neonates and young infants using inulin as marker. <i>AAPS Journal</i> , 2022, 24, 38.	2.2	6
128	Treatment of Pulmonary Embolism in an Extremely Obese Patient. <i>Obesity Surgery</i> , 2009, 19, 1186-1189.	1.1	5
129	Remifentanyl versus fentanyl during cardiac surgery on the incidence of chronic thoracic pain (REFLECT): study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 466.	0.7	5
130	Population pharmacokinetics of oxycodone in plasma and cerebrospinal fluid after epidural and intravenous administration. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 649-656.	2.4	5
131	Pre- and Postnatal Maturation are Important for Fentanyl Exposure in Preterm and Term Newborns: A Pooled Population Pharmacokinetic Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 401-412.	1.6	5
132	Supervised Multidimensional Item Response Theory Modeling of Pediatric Iatrogenic Withdrawal Symptoms. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 904-912.	1.3	4
133	Disease History and Medication Use as Risk Factors for the Clinical Manifestation of Type 1 Diabetes in Children and Young Adults: An Explorative Case Control Study. <i>PLoS ONE</i> , 2014, 9, e87408.	1.1	4
134	Total bodyweight and sex both drive pharmacokinetic variability of fluconazole in obese adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2217-2226.	1.3	4
135	Exploring the Relationship Between Morphine Concentration and Oversedation in Children After Cardiac Surgery. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 1231-1236.	1.0	3
136	Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations. <i>Pediatric Research</i> , 2021, 90, 1201-1206.	1.1	3
137	Towards Evidence-Based Weaning: a Mechanism-Based Pharmacometric Model to Characterize Iatrogenic Withdrawal Syndrome in Critically Ill Children. <i>AAPS Journal</i> , 2021, 23, 71.	2.2	3
138	Zebrafish larvae as experimental model to expedite the search for new biomarkers and treatments for neonatal sepsis. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 1-34.	0.3	3
139	Quantifying the Pharmacodynamics of Morphine in the Treatment of Postoperative Pain in Preverbal Children. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 99-109.	1.0	3
140	Comment on "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials". <i>Clinical Pharmacokinetics</i> , 2018, 57, 1471-1472.	1.6	2
141	Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools. <i>AAPS Journal</i> , 2019, 21, 11.	2.2	2
142	Comment on: "Preterm Physiologically Based Pharmacokinetic Model, Part I and Part II". <i>Clinical Pharmacokinetics</i> , 2021, 60, 677-679.	1.6	2
143	Predicting Unacceptable Pain in Cardiac Surgery Patients Receiving Morphine Maintenance and Rescue Doses: A Model-Based Pharmacokinetic-Pharmacodynamic Analysis. <i>Anesthesia and Analgesia</i> , 2021, 132, 726-734.	1.1	2
144	A Follow-up Study on BMI-SDS and Insulin Resistance in Overweight and Obese Children at Risk for Type 2 Diabetes Mellitus. <i>Global Pediatric Health</i> , 2015, 2, 2333794X1456845.	0.3	1

#	ARTICLE	IF	CITATIONS
145	Pharmacokinetics and Pharmacodynamics of Drugs in Obese Pediatric Patients: How to Map Uncharted Clinical Territories. Handbook of Experimental Pharmacology, 2019, 261, 231-255.	0.9	1
146	Sedation With Midazolam After Cardiac Surgery in Children With and Without Down Syndrome: A Pharmacokinetic-Pharmacodynamic Study. Pediatric Critical Care Medicine, 2021, 22, e259-e269.	0.2	1
147	Optimisation of fluconazole therapy for the treatment of invasive candidiasis in preterm infants. Archives of Disease in Childhood, 2022, 107, 400-406.	1.0	1
148	Population pharmacokinetics of intravenous cefotaxime indicates that higher doses are required for critically ill children. Journal of Antimicrobial Chemotherapy, 2022, 77, 1725-1732.	1.3	1
149	ORGAN FAILURE AND C-REACTIVE PROTEIN BOTH AFFECT MIDAZOLAM CLEARANCE IN CRITICALLY ILL CHILDREN: A POPULATION PK MODEL. Archives of Disease in Childhood, 2016, 101, e1.8-e1.	1.0	0
150	Authorâ€™s Reply to Reith: â€œHigher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adultsâ€. Clinical Pharmacokinetics, 2018, 57, 1357-1358.	1.6	0
151	Authorâ€™s Reply to Reith: â€œMorbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophenâ€. Clinical Pharmacokinetics, 2018, 57, 897-899.	1.6	0
152	Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis. Pharmaceutical Research, 2021, 38, 1711-1720.	1.7	0